ISPOR 2026 Home
  • About
    • News Center
  • Program
    • Program
    • Posters
    • Student Program
    • Learning Formats
    • Program Committee
    • Plenary Sessions
  • Exhibits & Sponsorship
    • Exhibitor Directory
    • Sponsors
    • Media Partners
  • Photo Gallery
large-circle

ISPOR 2026

Sunday, May 17 - Wednesday, May 20

  • Home
  • Events
  • Past Conferences
  • ISPOR 2026
  • Program
  • Program
  • Presentation
  • PSYCHOMETRIC VALIDATION OF THE QLQ-AA/PNH-54 BASED ON A POOLED DATASET OF A CLINICAL TRIAL AND TWO REAL-WORLD STUDIES OF CROVALIMAB IN PARTICIPANTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

    Mar 18, 2026, 21:38 PM
  • EVOLUTION OF FDA COMPANION DIAGNOSTICS

    Mar 18, 2026, 21:38 PM
  • COST ANALYSIS AND HEALTHCARE RESOURCE UTILIZATION AFTER OPEN LIVER RESECTION FROM A RANDOMIZED CONTROL TRIAL

    Mar 18, 2026, 21:38 PM
  • LONG-TERM OUTCOMES OF FIBROMYALGIA PATIENTS WITH AND WITHOUT INSOMNIA: A REAL-WORLD COHORT STUDY

    Mar 18, 2026, 21:38 PM
  • A LANDSCAPE ASSESSMENT OF THE STATISTICAL AND ECONOMIC MODELING OF CURE IN ONCOLOGY

    Mar 18, 2026, 21:38 PM
  • COST EFFECTIVENESS OF FIRSEKIBART FOR THE TREATMENT OF ACUTE GOUT PATIENTS UNSUITABLE FOR STANDARD THERAPY IN CHINA

    Mar 18, 2026, 21:38 PM
  • COST-EFFECTIVENESS OF NOVEL ANDROGEN RECEPTOR INHIBITORS IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER: A U.S. ANALYSIS INCORPORATING TWO-WAY SENSITIVITY ASSESSMENT

    Mar 18, 2026, 21:38 PM
  • UNDERSTANDING PRIORITIES IN HEALTH ECONOMICS: MAPPING COST-EFFECTIVENESS AND DISEASE BURDEN TRENDS

    Mar 18, 2026, 21:38 PM
  • QUANTIFYING CDA-INESSS DIFFERENCES IN ONCOLOGY HTA: RECOMMENDATIONS, RE-ANALYSIS, AND PRICE REDUCTIONS (2024-2025)

    Mar 18, 2026, 21:38 PM
  • COST OF CARE AND BUDGET IMPACT OF NOVEL FIRST-LINE (1L) TREATMENTS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (LA/MUC) IN COSTA RICA

    Mar 18, 2026, 21:38 PM
  • RAPID AI-ENABLED PICO SCOPING TO SUPPORT EUROPEAN JOINT CLINICAL ASSESSMENTS: A 4TH-LINE METASTATIC COLORECTAL CANCER CASE STUDY

    Mar 18, 2026, 21:38 PM
  • THE ANALYTICAL FRAMEWORK OF CLINICAL TRIALS EVALUATING CLINICAL OUTCOMES OF ARTIFICIAL INTELLIGENCE-BASED DIGITAL HEALTH INTERVENTIONS FOR MENTAL HEALTH DISORDERS: A SYSTEMATIC LITERATURE REVIEW

    Mar 18, 2026, 21:38 PM
  • ANTI-OSTEOPOROSIS DRUGS PRESCRIPTIONS AMONG OSTEOPOROSIS PATIENTS WITH T2DM IN CHINA

    Mar 18, 2026, 21:38 PM
  • INDIVIDUAL PICO REVIEW AND HIERARCHY IN SYSTEMATIC LITERATURE REVIEWS: WHY GUIDELINE ADHERENCE MATTERS AND HOW REAL-SLRS REDUCE REWORK

    Mar 18, 2026, 21:38 PM
  • DO MULTIPLE PRESENTATIONS AFFECT THE DURATION OF U.S. DRUG SHORTAGES?

    Mar 18, 2026, 21:38 PM
  • COMPARING OUTCOME MODELING STRATEGIES FOR ZERO-INFLATED ABSENTEEISM IN REAL-WORLD DATA: IMPLICATIONS FOR INFERENCE ON ANXIETY SEVERITY

    Mar 18, 2026, 21:38 PM
  • ASSESSING THE VALUE OF LOST SCHOOLING DUE TO ILLNESS AMONG CHILDREN IN THE UNITED STATES

    Mar 18, 2026, 21:38 PM
  • FROM FEASIBILITY TO FINDINGS: SUPPORTING INDIRECT TREATMENT COMPARISONS WITH GENERATIVE AI

    Mar 18, 2026, 21:38 PM
  • COST-EFFECTIVENESS OF SEMAGLUTIDE FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN THE UNITED STATES

    Mar 18, 2026, 21:38 PM
  • A MODULAR ONCOLOGY REFERENCE MODEL FOR EARLY ECONOMIC EVALUATION: A CASE STUDY IN EGFR-MUTATED NSCLC

    Mar 18, 2026, 21:38 PM
  • «
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16 (current)
  • 17
  • 18
  • 19
  • 20
  • »
Quick Links

  • About
  • Media Center
  • Exhibits & Sponsorships
  • Contact Us
Policies & Legal

  • Antitrust Compliance
  • Code of Ethics
  • Diversity Policy
  • Funding Statement
  • Legal Disclaimer
  • Privacy Policy

Subscribe

Join ISPOR


ISPOR–The Professional Society for
Health Economics and Outcomes Research

Copyright © 2018 ISPOR. All rights reserved.

International Society for Pharmacoeconomics and Outcomes Research, Inc

Website Design & Development by Matrix Group